Cases | Controls | p-value | |
Subjects n | 64 | 64 | |
Male | 43 (67.1%) | 32 (50%) | 0.07 |
SS or AC | 21 (32.8%) | 21 (32.8%) | 1 |
Age years at stage 4 | 43±13.5 | 41.8±9.5 | 0.66 |
Smoking NS/ES (mean pack-years) | 43 (67.1%)/22 (34.3%) (5.5) | 37 (57.8%)/27 (42.1%) (5.7) | 0.36 |
Diabetes mellitus | 7 (10.9%) | 6 (9.3%) | 1 |
Pneumothorax | 8 (12.5%) | 5 (7.8%) | 0.56 |
High-risk occupational exposure | 24 (37.5%) | 11 (17.1%) | 0.01 |
PFT at stage 4 diagnosis | |||
FEV1 % predicted | 58.7±18.8 | 61.4±22.2 | 0.58 |
FVC % predicted | 62.2±18.6 | 69.6±22.8 | 0.06 |
DLCO % predicted | 50.7±16.7 | 53.3±17.0 | 0.35 |
CPI | 45.5±14.8 | 39.7±16.2 | 0.07 |
Treatment for sarcoidosis at stage 4 diagnosis | 53 (82.8%) | 58 (90.6%) | 0.29 |
CTS ≤10 mg per day | 13 (20.3%) | 15 (23.4%) | 0.83 |
CTS >10 mg per day | 32 (50%) | 33 (51.5%) | 1 |
Immunosuppressive drugs | 8 (12.5%) | 10 (15.6%) | 0.79 |
Data are presented as n (%) or mean±sd unless otherwise stated. SS: sub-Saharan origin; AC: Afro-Caribbean origin; NS: never-smoker; ES: ever-smoker; PFT: pulmonary function test; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiologic index (91.0−(0.65×DLCO)−(0.53×FVC)+(0.34×FEV1); CTS: corticosteroids.